Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Research And Development Expense of $167.34 million for the year ending 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -29.7% in Research And Development Expense from 2024 to 2025.
- This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 2,241.1%.
- Historical annual values: Fiscal year 2025: $167.34 million | Fiscal year 2024: $237.96 million | Fiscal year 2023: $134.95 million | Fiscal year 2022: $108.63 million | Fiscal year 2021: $104.13 million | Fiscal year 2020: $90.45 million | Fiscal year 2019: $109.45 million | Fiscal year 2018: $50.34 million | Fiscal year 2017: $22.89 million | Fiscal year 2016: $19.59 million | Fiscal year 2015: $7.15 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: